Feature|Videos|September 30, 2024
The Regulatory Stance on Oligonucleotide Enantiomers
Author(s)LCGC Editors
The panel dives into the regulatory stance on oligonucleotide enantiomers. The role of batch-to-batch reproducibility, new drug application (NDA) filing, and current guidelines are covered.
Advertisement
Episodes in this series
Regulatory guidelines must be considered when discussing oligonucleotide analysis and enantiomers. The panel reviews the current regulatory stance on this topic and common analytical bottlenecks relative to regulatory compliance.
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
Chromatographic and Mass Spectrometric Screening of Novel Psychoactive Substances in Seized Drug Analysis
2
Industry Roundup: Bruker Unveils Next-Generation Multiomics MS Tools at ASMS
3
Industry Roundup: Thermo Fisher Scales Orbitrap Platform Across Research, Biopharma, and Environmental Testing at ASMS 2026
4
Analytical Solutions for PFAS Testing - Routine to Discovery Analysis in Environmental Samples and Consumer Products
5